These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37182989)

  • 1. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.
    Tam A; Eustace N; Kassardjian A; West H; Williams TM; Amini A
    Surg Oncol Clin N Am; 2023 Jul; 32(3):497-514. PubMed ID: 37182989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SBRT for oligoprogressive oncogene addicted NSCLC.
    Basler L; Kroeze SG; Guckenberger M
    Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
    Dohopolski M; Iyengar P
    Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
    J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic options for oligoprogressive non-small cell lung cancer].
    Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
    Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
    Franceschini D; De Rose F; Cozzi S; Franzese C; Rossi S; Finocchiaro G; Toschi L; Santoro A; Scorsetti M
    Crit Rev Oncol Hematol; 2020 Apr; 148():102894. PubMed ID: 32062314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Jairam V; Park HS; Decker RH
    Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
    Kroeze SGC; Schaule J; Fritz C; Kaul D; Blanck O; Kahl KH; Roeder F; Siva S; Verhoeff JJC; Adebahr S; Schymalla MM; Glatzer M; Szuecs M; Geier M; Skazikis G; Sackerer I; Lohaus F; Eckert F; Guckenberger M
    Radiat Oncol; 2021 Jan; 16(1):4. PubMed ID: 33407611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
    Rusthoven CG; Yeh N; Gaspar LE
    Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of oligometastatic or oligoprogression cancer].
    Bourgier C; Latorzeff I; Fenoglietto P; Boisselier P; Charissoux M; Llacer C; Lemanski C; Riou O; Farcy-Jacquet MP; Azria D
    Cancer Radiother; 2019 Oct; 23(6-7):482-485. PubMed ID: 31495737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
    Gan GN; Weickhardt AJ; Scheier B; Doebele RC; Gaspar LE; Kavanagh BD; Camidge DR
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):892-8. PubMed ID: 24462383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local control strategies for management of NSCLC with oligoprogressive disease.
    Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
    Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Place of stereotactic radiotherapy in oligoprogressive non-small cell lung cancer].
    Bernard G; Klausner G; Blais E; Canova CH; Bourhis J; Troussier I
    Rev Med Suisse; 2022 Jun; 18(784):1125-1133. PubMed ID: 35647751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.
    Iyengar P; All S; Berry MF; Boike TP; Bradfield L; Dingemans AC; Feldman J; Gomez DR; Hesketh PJ; Jabbour SK; Jeter M; Josipovic M; Lievens Y; McDonald F; Perez BA; Ricardi U; Ruffini E; De Ruysscher D; Saeed H; Schneider BJ; Senan S; Widder J; Guckenberger M
    Pract Radiat Oncol; 2023; 13(5):393-412. PubMed ID: 37294262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions.
    Lang P; Gomez DR; Palma DA
    Semin Respir Crit Care Med; 2020 Jun; 41(3):369-376. PubMed ID: 32450591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Management of Oligometastases in Non-small Cell Lung Cancer - is Stereotactic Ablative Radiotherapy now Standard of Care?
    Ratnakumaran R; McDonald F
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):753-760. PubMed ID: 36117126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
    Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
    Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
    Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
    Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.